Andrew W Hahn

28PUBLICATIONS
169CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Cancer geneticsPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Mar 03, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma.

Kabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan

|Nov 07, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy.

Neha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida

|Sep 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotype.

Neha Venkatesh, Rebecca S Tidwell, Yao Yu

|Jul 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibition.

Andrew W Hahn, Rebecca S Tidwell, Patrick G Pilie

|Jun 05, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.

Andrew W Hahn, Ganiraju C Manyam, Brian F Chapin

|Apr 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav

Pageof 5

Frequent Collaborators

7 joint publications

Pavlos Msaouel

5 joint publications

Christopher J Logothetis

5 joint publications

Ana M Aparicio

5 joint publications

Neeraj Agarwal